Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury : systematic review and network meta‐analysis by Horner, D. et al.
This is a repository copy of Pharmacological thromboprophylaxis to prevent venous 
thromboembolism in patients with temporary lower limb immobilization after injury : 
systematic review and network meta analysis‐ .
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/152920/
Version: Published Version
Article:
Horner, D., Stevens, J.W. orcid.org/0000-0002-9867-7209, Pandor, A. 
orcid.org/0000-0003-2552-5260 et al. (4 more authors) (2020) Pharmacological 
thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower 
limb immobilization after injury : systematic review and network meta analysis. Journal of ‐
Thrombosis and Haemostasis, 18 (2). pp. 422-438. ISSN 1538-7933 
https://doi.org/10.1111/jth.14666
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
ジゴゴ 科|科   J Thromb Haemost. 2020;18:422438.wileyonlinelibrary.com/journal/jth
 
Receivedr ザ May ゴグゲゾ科 |科 Acceptedr ゴゲ October ゴグゲゾ
DOIr ゲグsゲゲゲゲ｠jthsゲジ葦葦葦  
O R I G I N A L  A R T I C L E
Pharmacological thromboprophylaxis to prevent venous 
thromboembolism in patients with temporary lower limb 
immobilization after injury: systematic review and network 
meta-analysis
Daniel Horner1,2 科|   John W. Stevens2科|   Abdullah Pandor2 科|   Tim Nokes3科|   
Jonathan Keenan3科|   Kerstin de Wit4 科|   Steve Goodacre2
This is an open access artic旭e under the terms of the Creative Commons Attribution Licensep which permits usep distribution and reproduction in any mediump 
provided the origina旭 work is proper旭y citeds
ｻ ゴグゲゾ Crown copyrights Journa旭 of Thrombosis and Haemostasis ｻ ゴグゲゾ Internationa旭 Society on Thrombosis and Haemostasiss
Manuscript hand旭ed byr Sabine Eichinger 
Fina旭 decisionr Sabine Eichingerp ゴゲ October ゴグゲゾ 
Systematic Review Registration Pandor Ap Goodacre Sp Horner Dp Stevens JWp C旭owes Mp Davis Sp Stevenson Ms Systematic review and cost､effectiveness ana旭ysis of thromboprophy､
旭axis for 旭ower 旭imb immobi旭isations PROSPERO ゴグゲゼ CRDジゴグゲゼグズ芦葦芦芦s Avai旭ab旭e atr httpr｠｠wwwscrdsyorksacsuk｠PROSP ERO｠disp旭 ayｧrecordsphpnID┎CRDジゴ グゲゼグズ 芦葦芦芦s 
1Emergency Departmentp Sa旭ford Roya旭 NHS 
Foundation Trustp Sa旭fordp UK
2Schoo旭 OF Hea旭th and Re旭ated Researchp 
The University of Sheffie旭dp Sheffie旭dp UK
3University Hospita旭s P旭ymouth NHS Trustp 
P旭ymouthp UK
4Department of Medicinep McMaster 
Universityp Hami旭tonp ONp Canada
Correspondence
Danie旭 Hornerp Emergency Departmentp 
Sa旭ford Roya旭 NHS Foundation Trustp Stott 
Lanep Sa旭fordp M葦 芦HDp UKs
Emai旭r danie旭hornerｺnhssnet
Funding Information
This study was funded by the United 
Kingdom Nationa旭 Institute for Hea旭th 
Research Hea旭th Techno旭ogy Assessment 
Programme ｪproject number ゲズ｠ゲ芦ゼ｠グ葦ｫs 
The views expressed in this report are those 
of the authors and not necessari旭y those 
of the NIHR HTA Programmes Any errors 
are the responsibi旭ity of the authorss The 
funders had no ro旭e in the study designq in 
the co旭旭ectionp ana旭ysisp and interpretation 
of dataq in the writing of the manuscriptq and 
in the decision to submit the manuscript for 
pub旭ications
Abstract
Background: Thromboprophy旭axis has the potentia旭 to reduce venous thromboem､
bo旭ism ｪVTEｫ fo旭旭owing 旭ower 旭imb immobi旭ization resu旭ting from injurys
Objectives: We aimed to estimate the effectiveness of thromboprophy旭axisp com､
pare different agentsp and identify any factors associated with effectivenesss
Methods: We undertook a systematic review and network meta､ana旭ysis ｪNMAｫ of 
randomized tria旭s reporting VTE or b旭eeding outcomes that compared thrombopro､
phy旭actic agents with each other or to no pharmaco旭ogica旭 prophy旭axisp for this in､
dications An NMA was undertaken for each outcome or agent usedp and a series of 
study､旭eve旭 network meta､regressions examined whether popu旭ation characteristicsp 
type of injuryp treatment of injuryp or duration of thromboprophy旭axis were associ､
ated with treatment effects
Results: Data from 葦芦ズゼ participants across ゲザ randomized tria旭s showed thatp com､
pared with no treatmentp 旭ow mo旭ecu旭ar weight heparin ｪLMWHｫ reduced the risk 
of any VTE ｪodds ratio ｬORｭr グsズゴq ゾズ鯵 credib旭e interva旭 ｬCrIｭr グsザゼ､グsゼゲｫp c旭inica旭旭y 
detected deep vein thrombosis ｪDVTｫ ｪORr グsザゾq ゾズ鯵 CrIr グsゲゴ､グsゾジｫ and pu旭monary 
embo旭ism ｪPEｫ ｪORr グsゲ葦q ゾズ鯵 CrIr グsグゲ､グsゼジｫp whereas fondaparinux reduced the risk 
of any VTE ｪORr グsゲザq ゾズ鯵 CrIr グsグズ､グsザグｫ and c旭inica旭旭y detected DVT ｪORr グsゲグq ゾズ鯵 
CrIr グsグゲ､グs芦葦ｫp with inconc旭usive resu旭ts for PE ｪORr グsジグq ゾズ鯵 CrIr グsグゲ､ゼsズザｫs
Conclusions: Thromboprophy旭axis with either fondaparinux or LMWH appears to 
reduce the odds of both asymptomatic and c旭inica旭旭y detected VTE in peop旭e with 
temporary 旭ower 旭imb immobi旭ization fo旭旭owing an injurys Treatment effects vary by 
outcome and are not a旭ways conc旭usives We were unab旭e to identify any treatment 
effect modifiers other than thromboprophy旭actic agent useds
科架 科 | 科ジゴザHORNER ET AL.
ゲ科 |科BACKGROUND
Venous thromboembo旭ic ｪVTEｫ disease is a major g旭oba旭 cause of 
morbidity and mortality.ゲpゴ An estimated ゲグ mi旭旭ion episodes are di､
agnosed year旭yq more than one､ha旭f of these episodes are provoked 
by hospita旭 admission｠procedures and resu旭t in significant 旭oss of 
disabi旭ity､adjusted 旭ife yearss3
Temporary 旭ower 旭imb immobi旭ization after injury is a significant 
contributor to overa旭旭 VTE burdens4 This risk may be modifiab旭es 
Existing evidence suggests that pharmaco旭ogica旭 prophy旭axis cou旭d 
reduce overa旭旭 VTE event rates in these patientsp but the proportiona旭 
reduction of symptomatic events remains unc旭earsズ Recent random､
ized contro旭旭ed tria旭s ｪRCTsｫ have used different pharmaco旭ogica旭 
agents ｪ旭ow mo旭ecu旭ar weight heparin ｬLMWHｭ and fondaparinuxｫp 
dosing regimens and outcome measuress葦､ゾ In additionp some centers 
are reporting recent experience with use of the direct ora旭 anticoag､
u旭ants ｪDOACsｫ for this indicationp despite the 旭ack of appropriate 
旭icensing and tria旭 data within this specific popu旭ationsゲグpゲゲ
Consequent旭yp there is wide variation in thromboprophy旭axis 
strategiesp and internationa旭 guide旭ines continue to offer conf旭icting 
advice for c旭inicianssゲゴ､ゲズ The overa旭旭 c旭inica旭 effectiveness of throm､
boprophy旭axis for this indication and the optima旭 agent｠dosing strat､
egy are yet to be defineds
We undertook a systematic review and network meta､ana旭ysis 
ｪNMAｫ to assess the effectiveness of pharmaco旭ogica旭 thrombopro､
phy旭axis at preventing VTE in patients with temporary 旭ower 旭imb 
immobi旭ization after injurys Our aim was to estimate the c旭inica旭 ef､
fectiveness for each pharmaco旭ogica旭 thromboprophy旭axis option and 
further compare regimens and agents to identify an optima旭 strategys
ゴ科 |科METHODS
The systematic review was undertaken in accordance with the 
genera旭 princip旭es recommended in the Preferred Reporting Items 
for Systematic Reviews and Meta､Ana旭yses ｪPRISMAｫ statementsゲ葦 
This review was part of a 旭arger project on thromboprophy､
旭axis for 旭ower 旭imb immobi旭ization that was registered on the 
PROSPERO internationa旭 prospective register of systematic reviews 
ｪCRDジゴグゲゼグズ芦葦芦芦ｫsゲゼ The fu旭旭 protoco旭 is avai旭ab旭e here ｪhttps r｠｠
wwwsjourn a旭s旭i brarysnihrsacsuk｠progr ammes｠ hta｠ゲズゲ芦ゼ グ葦｠ﾌ｠ｫs
ゴsゲ科|科E旭igibi旭ity criteria
Studies were considered e旭igib旭e for inc旭usion if they met the fo旭､
旭owing criteriar ｪaｫ RCTs or contro旭旭ed c旭inica旭 tria旭sq ｪbｫ adu旭ts ｪage 
┒ゲ葦 yearsｫ requiring temporary immobi旭ization ｪesgsp 旭eg cast or 
brace in an ambu旭atory settingｫ for an iso旭ated 旭ower 旭imb injuryq 
ｪcｫ chemica旭 thromboprophy旭axis with any LMWH agentp fonda､
parinuxp or ora旭 anticoagu旭ant ｪesgsp apixabanp dabigatran etexi旭atep 
rivaroxabanp edoxabanｫq ｪdｫ comparators inc旭uded p旭acebop no treat､
mentp aspirinp or a旭ternative treatmentq and ｪeｫ outcomes inc旭uded 
symptomatic or asymptomatic deep vein thrombosisp pu旭monary 
embo旭ism ｪPEｫp major b旭eeding ｪas defined within each studyｫp or 
morta旭itys Exc旭usion criteria for se旭ection inc旭uded studies that 
had not been designed as experimenta旭 studies ｪesgsp cohort stud､
iesp case contro旭 studiesｫq invo旭ved hospita旭 inpatient care or any 
patient requiring hospita旭 admission 旭onger than ザ daysq patients 
receiving mechanica旭 thromboprophy旭axis or undergoing ambu旭ant 
orthopedic surgery ｪesgsp arthroscopyp arthroscopic surgeryｫs
ゴsゴ科|科Outcome definitions
Given the cha旭旭enges of outcome reporting in this popu旭ationp we 
chose to prospective旭y define VTE events according to anatomica旭 
旭ocation and symptomato旭ogys Our aim was to provide fu旭旭 transpar､
ency of a旭旭 potentia旭旭y re旭evant outcomes and to high旭ight the specific 
data informing assessment of interventions
We defined proxima旭 deep vein thrombosis ｪDVTｫ as throm､
bosis occurring at or above the 旭eve旭 of the pop旭itea旭 trifurcations 
18 Symptomatic disease was defined as reported within individua旭 
tria旭sq any diagnosis of PE was considered to be symptomaticp as 
were presentations outside routine study fo旭旭ow､up with acute 
DVT symptoms and subsequent confirmation of diseases Howeverp 
in severa旭 studies patients were questioned on the symptoms of 
DVT ｪesgsp painp swe旭旭ingｫ when the cast was removedp at routine 
fo旭旭ow､ups If the patients reported any positive symptoms and 
routine sonography had detected DVTp the event was c旭assified 
as symptomatics The 旭imitations with this approach are high旭ighted 
旭ater in the discussion sections wAny VTExwas defined as the com､
posite of any PE and｠or any dista旭 or proxima旭 DVTp with or without 
symptomss
K E Y W O R D S
riskp immobi旭izationp venous thromboembo旭ismp castsp surgica旭p network meta､ana旭ysis
Essentials
ｨ Patients with injury and 旭ower 旭imb immobi旭ization are at 
increased risk of thromboembo旭isms
ｨ This network meta､ana旭ysis ana旭yzed 葦芦ズゼ patients ran､
domized to thromboprophy旭axis or contro旭s
ｨ Overa旭旭p pharmaco旭ogica旭 prophy旭axis significant旭y re､
duced the odds of any venous thromboembo旭ism ｪVTEｫs
ｨ Individua旭ized treatment may be an optima旭 strategy and 
requires further studys
ジゴジ科 |科 科架 HORNER ET AL.
We cou旭d not retrospective旭y app旭y consensus definitions of 
symptomato旭ogy or major b旭eeding to individua旭 study resu旭tss19 
These issues and their potentia旭 impact on study resu旭ts are exp旭ored 
further in the discussion sections
ゴsザ科|科Information sources and searches
Ten e旭ectronic databases ｪinc旭uding MEDLINEp EMBASEp and the 
Cochrane Libraryｫ were searcheds The search strategy used free text 
and thesaurus terms and combined synonyms re旭ating to the condi､
tion ｪesgsp venous thromboembo旭ism in peop旭e with 旭ower 旭imb immo､
bi旭izationｫ with synonyms re旭ating to the interventions ｪesgsp LMWHp 
aspirinp ora旭 anticoagu旭antsｫs No 旭anguage restrictions were useds 
Searches were supp旭emented by hand､searching the reference 旭ists 
of a旭旭 re旭evant studies ｪinc旭uding existing systematic reviewsｫp per､
forming a citation search of re旭evant artic旭esp contacting key experts 
in the fie旭dp and undertaking systematic keyword searches of the 
Wor旭d Wide Web using the Goog旭e search engines Further detai旭s on 
the search strategy can be found in Tab旭e Sゲ ｪsupporting informationｫs
ゴsジ科|科Study se旭ection
A旭旭 tit旭es were examined for inc旭usion by one reviewer ｪAsPsｫq any ci､
tations that clearly did not meet the inclusion criteria were excluded. 
A旭旭 abstracts and fu旭旭､text artic旭es were then examined indepen､
dent旭y by two reviewers ｪAsPs and DsHsｫs Any disagreements in the 
se旭ection process were reso旭ved through discussion or if necessaryp 
arbitration by a third reviewer ｪSsGsｫ and inc旭uded by consensuss
ゴsズ科|科Data extraction and qua旭ity assessment
Data re旭ating to study designp methodo旭ogica旭 qua旭ityp and out､
comes were extracted by one reviewer into a standardized data ex､
traction form and independent旭y checked for accuracy by a seconds
The methodo旭ogica旭 qua旭ity of each inc旭uded study was eva旭uated 
using a revised Cochrane Risk of Bias too旭 for randomized tria旭s ｪRoB 
ゴsグｫs20 The origina旭 too旭 21 was updated because of questionab旭e in､
ter､rater agreementp subjectivity in assigning risk of bias judgmentsp 
and bias judgments assigned at the tria旭 旭eve旭sゴゴ､ゴズ An overa旭旭 judge､
ment of bias was assigned as 旭ow risk if a旭旭 domains were judged as 旭ow 
risk of biasq high risk if at 旭east one domain was judged to be at high risk 
of bias ｪor if the study has some concerns for mu旭tip旭e domains in a way 
that substantia旭旭y 旭owers confidence in the resu旭tｫp and some concerns 
if any bias ｪother than high riskｫ was noted in at 旭east one domains20
ゴs葦科|科Data synthesis and ana旭ysis
For each outcome of interestp an NMA was performed to a旭旭ow a 
simu旭taneous comparison between interventions using a旭旭 avai旭ab旭e 
studiess The data were the number of events out of the number of 
patients randomized to each c旭ass of interventionp which were as､
sumed to arise from an under旭ying binomia旭 distributions LMWH 
agents were co旭旭ated and considered as a sing旭e interventions The 
probabi旭ities of an event for each intervention were mode旭旭ed using a 
旭ogistic mode旭 to estimate odds ratios ｪORsｫs The reference interven､
tion was defined as p旭acebop no treatmentp or aspirin in the NMAs 
The different thromboprophy旭axis drugs were treated as separate 
interventions ｪisesp LMWHp DOACsp and fondaparinuxｫ in the NMA 
on the basis of having different mechanisms of action and different 
adverse event profi旭ess
The ana旭ysis was imp旭emented using Markov chain Monte Car旭o 
simu旭ation using WinBUGS software Version ゲsジsザ ｪMRC Biostatistics 
Unitｫsゴ葦 A fixed effect mode旭 was used to estimate the effects of 
LMWH and fondaparinux re旭ative to contro旭 in the avai旭ab旭e stud､
ies ｪisesp a conditiona旭 inferenceｫs In additionp a random effects mode旭 
was used to a旭旭ow for heterogeneity in the effects of interventions 
between studies and to estimate whether the interventions can have 
an effect in future studiess Resu旭ts were presented using ORsp ゾズ鯵 
credib旭e interva旭s ｪCrIｫp and ゾズ鯵 predictive interva旭s for the OR in a 
random旭y chosen study re旭ative to the contro旭p with the probabi旭ity 
of each intervention being the bests
We a旭so eva旭uated the fo旭旭owing potentia旭 treatment effect mod､
ifiers in a series of meta､regressionsr ｪaｫ Popu旭ation characteristics 
ｪproportion ma旭ep base旭ine risk of VTEｫq ｪbｫ type of injury ｪfracturesp 
Achi旭旭es tendon rupturep other soft､tissue injuryｫq ｪcｫ treatment of in､
jury ｪsurgica旭 versus conservativep above versus be旭ow knee immo､
bi旭izationｫq ｪdｫ thromboprophy旭actic agent usedq and ｪズｫ duration of 
thromboprophy旭axiss
ザ科 |科RESULTS
ザsゲ科|科Study se旭ection
The 旭iterature searches identified ゲゲグズ citationss Of thesep ゲザ RCTs 
met the inclusion criteria.葦p芦pゾpゴゼ､ザ葦 A f旭ow chart describing the pro､
cess of identifying re旭evant 旭iterature can be found in Figure ゲs 
Studies exc旭uded after fu旭旭 text review are 旭isted in Tab旭e Sゴp a旭ong 
with the rationa旭e for exc旭usions
ザsゴ科|科Characteristics of inc旭uded studies
The design and patient characteristics of the ゲザ inc旭uded stud､
ies葦p芦pゾpゴゼ､ザ葦 are summarized in Tab旭e ゲs A旭旭 studies were pub､
旭ished between ゲゾゾザ and ゴグゲゼs In tota旭p 葦芦ズゼ patients were 
inc旭uded and randomized across ゲグ different countries ｪCanadap芦pゴ芦 
Chinap葦 Denmarkpゴゾpザジ Francepザズ Germanypゴゼpザグpザゲpザズ Ita旭ypザズ 
Nether旭andspゾpザズpザ葦 Russiapザズ Spainザズ and Swedenザゴpザザｫ to receive ei､
ther intervention or contro旭s LMWH injections were the primary in､
terventionp using variab旭e agents ｪcertoparinp30 da旭teparinp芦pゴ芦pザゴpザザ 
nadroparinpゾpザゲpザズpザ葦 reviparinpゴゼpザジ and tinzaparinｫ29 and dosing 
科架 科 | 科ジゴズHORNER ET AL.
regimenss Two studies used fondaparinuxsゾpザズ E旭even of the studies 
compared LMWH thromboprophy旭axis to no thromboprophy旭axisp 
one three､arm study compared LMWH with fondaparinux with no 
thromboprophy旭axisp and one study compared LMWH with fonda､
parinuxs We found no randomized tria旭s comparing DOACs with 
any other thromboprophy旭axis strategy for this patient groups One 
study used aspirin as a contro旭 grouppゴゼ with others using p旭acebo 
injections or nothing dependent on designs葦p芦pゴ芦､ザジpザ葦 In genera旭p 
most studies exc旭uded patients at highest risk of VTE ｪesgsp active 
cancerp葦p芦pゾpザゴpザザ previous VTE葦p芦pゾpゴ芦pザグ､ザジpザ葦 or first､degree fami旭y 
history of VTE葦pザ葦ｫs
Five studies were open 旭abe旭 with subjective screening 
outcomes ｪdup旭ex sonography or ph旭ebography on cast re､
mova旭ｫsゴゾ､ザゲpザズpザ葦 Six studies used doub旭e b旭inding within the 
designs葦p芦pゴ芦pザゴ､ザジ A旭though a旭旭 studies inc旭uded adu旭t patients 
with an iso旭ated 旭ower 旭imb injury requiring temporary immobi､
旭izationp there was wide variation in terms of injury types Five 
studies inc旭uded on旭y patients with fracturesp葦p芦pゾpゴ芦pザゴ one of pa､
tients with Achi旭旭es tendon rupturesp33 and the remaining seven 
studies inc旭uded patients with mixed patho旭ogysゴゼpゴゾ､ザゲpザジ､ザ葦 
Depending on the type of injuryp the management of 旭ower 旭imb 
injury inc旭uded conservative treatmentpゾpザグpザゲpザズ surgica旭 man､
agementp葦p芦pゴ芦pザゴpザザ or both.ゴゾpザジpザ葦 In eight studiesp葦p芦pゾpゴ芦pザゴ､ザズ 
patients were recruited within ジ days of injuryp whereasp in the 
remaining studiespゴゼpゴゾ､ザゲpザ葦 the time to recruitment was not 
stateds The duration of immobi旭ization ranged from ゲジ days28 to 
44 days.ザゴpザジ In two studiesp a旭旭32 or some ｪapproximate旭y one､
thirdｫ34 patients first received prophy旭axis before randomizationq 
these studies were inc旭uded because any fina旭 impact on out､
come wou旭d 旭ike旭y take the form of reduction in VTE outcome 
eventss In additionp the resu旭ts of these tria旭s remain re旭evant to 
the study question in 旭ight of current regimes suggesting prophy､
旭axis shou旭d continue for the duration of immobi旭ization ｪusua旭旭y 
ジ､葦 weeksｫs
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Full text articles included 
(n = 13 studies)
Record screened by 
abstract 
(n = 214)
Full -text articles excluded, 
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(n = 23)
Population not isolated 
lower limb injury 
requiring temporary 
immobilisation (n = 1), not 
a randomised or controlled 
clinical trial (n = 6), review/ 
comment/ editorial (n = 10),
abstract /duplicate/ sub-
study of an included full 
text paper (n = 6)
Studies included in 
quantitative synthesis 
(meta-analysis)
(n = 13 studies)
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TA B L E  ゲ 科 Summary of design and patient characteristics
Author year Country (sites) Design Population
Time between 
injury and 
recruitment/ 
immobilization 
duration (mean)
Prophylaxis before 
randomization Intervention Comparator
Outcome measure 
(primary)
Goe旭 et a旭s28 Canada ｪNRｫ Rp DBa Adu旭ts ｪゲ芦､ゼズ yq mean 
agep ジゲ yq ma旭ep 葦ゴ鯵ｫs 
Fractures be旭ow knees 
Surgica旭旭y treated 
Outpatients N ┎ ザグズ
Within ジ芦h 
Immobi旭ization 
duration: 14 db
No LMWH ｪda旭teparinp 
ズグググ IU｠d for ゲジ dq 
administered by s.c. 
injectionq comp旭iancep 
┒ゾズ鯵ｫ
Matching p旭acebo 
for ゲジ d ｪcomp旭i､
ance with injec､
tionsp ┒ゾズ鯵ｫ
Incidence of DVT de､
termined by bilateral 
venography at end of 
treatment
Jørgensen et 
al., 2002 29
Denmark ｪザ 
centersｫ
Rp OLa Adu旭ts ｪ┒ゲ芦 yq mean 
agep ジ芦 yq ma旭ep ズゼ鯵ｫ 
Fracture or soft､tissue 
injuryq Conservative 
or surgica旭旭y treated 
Outpatients N ┎ ザググ
NR 
Immobi旭ization 
duration: 
ズsズ weeks
No LMWH ｪtinzaparinp 
ザズググ IU｠d for dura､
tion of cast immobi旭i､
zationq administered 
by s.c. injection; 
comp旭iancep NRｫ
No treatment Incidence of DVT de､
termined by unilateral 
venography after p旭aster 
cast removal
Kock et a旭sp 
ゲゾゾズ30
Germany ｪNRｫ Rp OL Adu旭ts ｪゲ芦､ゼズ yq mean 
agep ザジ yq ma旭ep 葦ゲ鯵ｫ 
Fracture or soft､tissue 
injury Conservative 
treatment Outpatients 
N ┎ ジゴ芦
NR 
Immobi旭ization 
durationr ゲゼ db
No LMWH ｪcertoparinp 
ザグググ IU｠d for dura､
tion of cast immobi旭i､
zationq administered 
by s.c. injection; 
comp旭iancep NRｫ
No treatment Incidence of DVT deter､
mined by dup旭ex sonog､
raphy and confirmed 
by ph旭ebography after 
p旭aster cast remova旭
Kujath et a旭s, 
1993 31
Germany ｪゲ 
hospita旭ｫ
Rp OL Patients over ゲ葦 y ｪmean 
agep ザジ yq ma旭ep ズ芦鯵ｫ 
Fracture or soft､tissue 
injury Conservative 
treatment Outpatients 
N ┎ ザグ葦
NR 
Immobi旭ization 
duration: 
ゲズsゼ db
No LMWH ｪNadroparinp 
ゴ芦ズグ IU｠d for dura､
tion of cast immobi旭i､
zationq administered 
by s.c. injection; 
comp旭iancep NRｫ
No treatment Incidence of DVT deter､
mined by compression 
u旭trasound and ph旭ebog､
raphy ｪpositive findings 
on旭yｫ after p旭aster cast 
removal
Lapidus et 
al., ゴググゼa 32
Sweden ｪゲ 
centraｫ
Rp DBa Adu旭ts ｪゲ芦､ゼズ yq mean 
agep ジグ yq ma旭ep ゼゾ鯵ｫ 
Soft､tissue injury 
ｪAchi旭旭es tendon rup､
tureｫ Surgica旭旭y treated 
Outpatients N ┎ ゲグズ
Within ゼゴ 
h of injury 
Immobi旭ization 
duration: 43 db
No LMWH ｪda旭tepa､
rinp ズグググ IU｠d for 
葦 weeksq administered 
by s.c. injection; com､
p旭iancep NRｫ
Matching p旭acebo 
for 葦 weeks 
ｪcomp旭iance with 
injectionsp NRｫ
Incidence of DVT de､
termined by unilateral 
dup旭ex sonography 
and confirmed by 
ph旭ebography
Lapidus et 
al., ゴググゼb 33
Sweden ｪゲ 
centraｫ
Rp DBa Adu旭ts ｪゲ芦､ゼズ yq mean 
agep ジ芦 yq ma旭ep ジ葦鯵ｫ 
Fracture of the ank旭e 
Surgica旭旭y treated 
Outpatients N ┎ ゴゼゴ
Within ゼゴ 
h of injury 
Immobi旭ization 
duration: 44 db
Yesp a旭旭 patients re､
ceived ゲ week of 
initial treatment 
with da旭teparin 
ｪズグググ IU｠dｫ 
before 
randomization
LMWH ｪda旭tepa､
rinp ズグググ IU｠d for 
ズ weeksq administered 
by s.c. injection; com､
p旭iancep ゾジs葦鯵ｫ
Matching p旭acebo 
for ズ weeks 
ｪcomp旭iance with 
injectionsp ゾジs葦鯵ｫ
Incidence of DVT con､
firmed by uni旭atera旭 
ph旭ebography after cast 
remova旭 or compression 
u旭trasonography where 
the ph旭ebography fai旭ed
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Author year Country (sites) Design Population
Time between 
injury and 
recruitment/ 
immobilization 
duration (mean)
Prophylaxis before 
randomization Intervention Comparator
Outcome measure 
(primary)
Lassen et a旭s, 
ゴググゴ k34
Denmark ｪ葦 
hospita旭sｫ
Rp DBa Adu旭ts ｪ┒ゲ芦 yq median 
agep ジゼ yq ma旭ep ズゴ鯵ｫ 
Fracture or rup､
ture of the Achi旭旭es 
tendon Conservative 
or surgica旭旭y treated 
Outpatient ｪin most 
casesｫ N ┎ ジジグ
     
 Within ジ d 
of injury 
Immobi旭ization 
duration: 44 db
Yesp ap､
proximate旭y 
one､third in 
each group 
received 
other 
LMWH for 
up to ジ d 
before rand､
omization
LMWH ｪreviparinp 
ゲゼズグ IU｠d for duration 
of cast immobi旭izationq 
administered by s.c. 
injectionq comp旭iancep 
approximate旭y ゲググ鯵ｫ
Matching 
p旭acebo for 
duration of cast 
immobi旭ization 
ｪcomp旭iance 
with injectionsp 
approximate旭y 
ゲググ鯵ｫ
Incidence of DVT 
determined by 
uni旭atera旭 venog､
raphy after p旭aster 
cast remova旭 ｪor 
ear旭ier if c旭inica旭 
symptoms of 
thrombosis 
suspectedｫ
   
Se旭by et a旭., 
ゴグゲズ 8
Canada ｪゲザ 
hospita旭sｫ
Rp DBa Patients over ゲ葦 y ｪmean 
agep ジゾ yq ma旭ep ズゴ鯵ｫ 
fractures Surgica旭旭y 
treated Outpatients 
N ┎ ゴ葦ズ
Within ゼゴ 
h of injury 
Immobi旭ization 
duration: 43 db
No LMWH ｪda旭teparinp 
ズグググ IU｠d for ゲジ dq 
administered by s.c. 
injectionq comp旭iancep 
ゾグ鯵ｫ
Matching p旭acebo 
for ゲジ d ｪcomp旭i､
ance with injec､
tionsp ゾゴ鯵ｫ
Symptomatic VTE within 
ザ months after surgery or 
asymptomatic proxima旭 
DVT determined by bi旭at､
era旭 Dopp旭er u旭trasound 
at end of treatment
van 
Adrichem et 
al., ゴグゲゼ ザ葦
The Nether旭ands 
ｪ芦 hospita旭sｫ
Rp OLa Adu旭ts ｪ┒ゲ芦 yq mean 
agep ジ葦 yq ma旭ep ジゾsゾ鯵ｫ 
Fracture or soft､tissue 
injury Conservative 
or surgica旭旭y treated 
Outpatients N ┎ ゲズゲゾ
NR 
Immobi旭ization 
duration: 4.9 
weeksb
No LMWH ｪnadroparinp 
ゴ芦ズグ IU｠d or da旭tepa､
rinp ｬゴズググ IU｠d for 
┑ゲググ kg or ズグググ IU｠d 
┒ゲググ kgｭ for duration 
of cast immobi旭izationq 
administered by s.c. 
injectionq comp旭iancep 
芦ゼ鯵ｫ
No treatment Incidence of symptomatic 
VTE within ザ months 
after the procedures DVT 
determined by abnormal 
compression u旭trasound
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Author year Country (sites) Design Population
Time between 
injury and 
recruitment/ 
immobilization 
duration (mean)
Prophylaxis before 
randomization Intervention Comparator
Outcome measure 
(primary)
Zheng et a旭s, 
ゴグゲゼ 葦
China ｪザ 
hospita旭sｫ
Rp DBa Adu旭ts ｪ┒ゲ芦 yq mean agep 
ジゼs芦 yq ma旭ep 葦ゴsザ鯵ｫ 
Fracture of the ank旭e or 
foot Surgica旭旭y treated 
Outpatients N ┎ 芦ゲジ
Mean 3.3 d 
Immobi旭ization 
durationr NR
No LMWH ｪNR but given 
once dai旭y for ゲジ dq 
administered by s.c. 
injectionq comp旭iancep 
NRｫ
Matching p旭acebo 
for ゲジ d ｪcomp旭i､
ance with injec､
tionsp NRｫ
Incidence of VTEs DVT 
determined by bilateral 
Dopp旭er u旭trasound
Geh旭ing et 
al., 1998 ゴゼ
Germany ｪゲ 
hospita旭ｫ
R Patients over ゲ葦 y ｪmean 
agep ザ葦 yq ma旭ep ジゾ鯵ｫ 
Fracture or soft､tissue 
injury Management 
approach unc旭ear ｪbut 
majority appear to 
be surgica旭旭y treatedｫ 
Outpatients N ┎ ゴ芦ゼ
NR 
Immobi旭ization 
durationr NR
NR LMWH ｪreviparinp 
ゲゼズグ IU｠d adminis､
tered by s.c. injection; 
comp旭iancep NRｫ
Aspirin 
ｪゲグググ mg｠d ad､
ministered orally; 
comp旭iancep NRｫ
Incidence of DVT deter､
mined by dup旭ex sonogra､
phy ｪa旭旭ｫ or ph旭ebography 
ｪif thrombosis suspectedｫ
Bruntink et a旭s, 
ゴグゲゼ ｪザ､arm 
studyｫ 9
The Nether旭ands 
ｪゼ hospita旭sｫ
Rp SBa Adu旭ts ｪ┒ゲ芦 yq mean 
agep ジゼ yq ma旭ep ジゴ鯵ｫ 
Fracture of the ank旭e 
or foot Conservative 
treatment Outpatients 
N ┎ ジ葦ゼ
Within ゼゴ 
h of injury 
Immobi旭ization 
durationr ザゾsズ 
db
No LMWH nadroparinp 
ゴ芦ズグ IU｠d for dura､
tion of cast immobi旭i､
zationq administered 
by s.c. injection; 
comp旭iance approxi､
mate旭y ゲググ鯵ｫ
ゲs Fondaparinux 
ｪゴsズ mg｠d for 
duration of cast 
immobi旭izationq 
administered by 
s.c. injection; 
comp旭iancep 
approximate旭y 
ゲググ鯵ｫ ゴs No 
treatment
Incidence of DVT 
determined by dup旭ex 
sonography after the 
remova旭 of the cast ｪor 
ear旭ier if thrombosis was 
suspectedｫ
Samama et 
al., 2013 ザズ
Francep 
Russiap The 
Nether旭andsp 
Spainp 
Germanyp Ita旭y 
ｪゾザ centersｫ
Rp OLa Adu旭ts ｪ┒ゲ芦 yq mean 
agep ジ葦 yq ma旭ep ジ葦s葦鯵ｫ 
Fracture or soft､tissue 
injury Conservative 
treatment Outpatients 
N ┎ ゲザジゾ
Within ゼゴ 
h of injury 
Immobi旭ization 
durationr ザザsゼ 
db
No LMWH ｪnadroparinp 
ゴ芦ズグ IU｠d for dura､
tion of cast immobi旭i､
zationq administered 
by s.c. injection; 
comp旭iancep NRｫ
Fondaparinux 
ｪゴsズ mg｠d for 
duration of cast 
immobi旭izationq 
administered by 
s.c. injection; 
comp旭iancep NRｫ
Incidence of VTEs 
Compression u旭trasonog､
raphy and｠or venography 
performed for suspected 
DVT after cast remova旭
Abbreviationsr DBp doub旭e b旭indq DVTp deep vein thrombosisq LMWHp 旭ow mo旭ecu旭ar weight heparinq NRp not reportedq OLp open 旭abe旭q Rp randomized contro旭旭ed tria旭q SBp sing旭e b旭indq sscp subcutaneousq 
VTEp venous thromboembo旭isms
aB旭inded outcome assessments 
bMeans ca旭cu旭ated from reported group means of intervention and comparator armss 
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ザsザ科|科Riｾsk of bias within and across studies
The overa旭旭 methodo旭ogica旭 qua旭ity of the ゲザ inc旭uded stud､
ies is summarized in Figure ゴ and Tab旭e ゴs Overa旭旭p risk of bias 
was present in a旭旭 studiess Ten studies raised some concerns of 
bias.葦p芦pゾpゴ芦pゴゾpザゴ､ザ葦 The potentia旭 sources of bias most frequent旭y 
identified inc旭uded concerns about the randomization process 
ｪa旭旭ocation concea旭ment was not reported in nine studiesｫp葦pゴゼ､ザジ 
b旭inding ｪopen､旭abe旭 designｫゾpゴゼpゴゾ､ザゲpザズpザ葦p and ana旭yses intentions 
ｪon旭y one study provided sufficient information on se旭ection of 
the reported resu旭tｫsザ葦 High risk of bias was principa旭旭y attribut､
ab旭e to outcome assessmentq in three open､旭abe旭 studiesp outcome 
assessment was performed on a旭旭 patients with compression u旭､
trasound and subsequent ph旭ebography used to confirm positive 
sonographic findingss ゴゼpザグpザゲ
ザsジ科|科Effects of interventions
Detai旭s of the tota旭 participant numbers in each ana旭ysisp event ratesp 
and further key outcome resu旭ts of the individua旭 primary studies are 
provided in Tab旭e ザs A旭旭 ゲザ studies reported outcomes for any VTEp 
PEp and major b旭eedings The rate of any VTE in the contro旭 group 
ranged from ゲs芦鯵 to ジグsジ鯵s The rate of PE in the contro旭 group was 
zero in eight studies and ranged from グsゼ鯵 to ゴsゲ鯵 in the other fours 
There was on旭y one major b旭eeding event across a旭旭 contro旭 groupss
NMA was undertaken to compare the effectiveness of two a旭､
ternative forms of thromboprophy旭axis ｪLMWH or fondaparinuxｫ to 
no thromboprophy旭axis ｪaspirinp p旭acebop or no treatmentｫs Figure ザ 
presents the network of evidences A旭旭 ゲザ studies were inc旭uded in the 
ana旭ysis and provided information on at 旭east one of the outcomes 
being ana旭yzeds A summary of the resu旭ts of fixed effect and random 
effects NMA are provided in Tab旭e ジs
ザsジsゲ科|科C旭inica旭旭y detected DVT ｪsymptomaticｫ
Data were avai旭ab旭e from a旭旭 ゲザ studiess葦p芦pゾpゴゼ､ザ葦 The risk of c旭ini､
ca旭旭y detected DVT ｪsymptomaticｫ was 旭ower in adu旭t outpatients 
with 旭ower 旭imb immobi旭ization who received LMWH ｪORp グsジグq 
ゾズ鯵 CrIr グsゲゴ､グsゾゾｫ and fondaparinux ｪORp グsゲグq ゾズ鯵 CrIr グsグゲ､
グsゾジｫ compared with contro旭s Fondaparinux is 旭ike旭y to be the most 
effective treatment ｪprobabi旭ity of being the most effective ┎ グsゾゲｫs
ザsジsゴ科|科Asymptomatic DVTr proxima旭 segment
Data were avai旭ab旭e from eight studiess葦p芦pゴゼ､ザグpザザpザズ The risk of asympto､
matic DVT ｪproxima旭 segmentｫ was 旭ower in adu旭t outpatients with 旭ower 
旭imb immobi旭ization who received LMWH ｪORp グsゴゲq ゾズ鯵 CrIr グsグジ､グs芦ゴｫ 
compared with contro旭s A simi旭ar effect was found for fondaparinuxp a旭､
though the resu旭ts were inconc旭usive ｪORp グsゴ芦q ゾズ鯵 CrIr グsグゴ､ザsジゴｫs
ザsジsザ科|科Asymptomatic DVTr dista旭
Data were avai旭ab旭e from eight studiess葦p芦pゴゼ､ザグpザジpザズ The risk of 
asymptomatic DVT ｪdista旭ｫ was 旭ower in adu旭t outpatients with 
旭ower 旭imb immobi旭ization who received fondaparinux ｪORp グsゲゲq 
ゾズ鯵 CrIr グsグザ､グsザズｫ compared with contro旭q fondaparinux is 
旭ike旭y to be the most effective treatment ｪprobabi旭ity of being 
the most effective ┎ ゲsググｫs There was insufficient evidence of an 
F I G U R E  ゴ 科 Risk of bias assessment graphr Review authorsｷ judgments about each methodo旭ogica旭 qua旭ity item across a旭旭 inc旭uded studies
Bias arising from randomisation process
Bias due to deviations from intended interventions
Bias due to missing outcome data
Bias in measurement of outcome
Bias in selection of reported result
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TA B L E  ゴ 科 Risk of bias assessment summaryr Review authorsｷ judgments about each methodo旭ogica旭 qua旭ity item for each inc旭uded study
Study
Bias arising from the 
randomization process
Bias from deviations from 
intended interventions
Bias due to missing 
outcome data
Bias in measurement of 
the outcome
Bias in selection of 
the reported result Overalla
Goe旭 et a旭s, 2009 28 Some concerns Low Low Low Some concerns Some concerns
Jørgensen et a旭s, 2002 29 Some concerns Some concerns Low Low Some concerns Some concerns
Kock et a旭s, ゲゾゾズ30 Some concerns Some concerns Low High Some concerns High
Kujath et a旭s, 1993 31 Some concerns Some concerns Some concerns High Some concerns High
Lapidus et a旭s, ゴググゼa 32 Some concerns Low Low Low Some concerns Some concerns
Lapidus et a旭s, ゴググゼb 33 Some concerns Low Low Low Some concerns Some concerns
Lassen et a旭s, 2002 34 Some concerns Low Low Low Some concerns Some concerns
Se旭by et a旭s, ゴグゲズ 8 Low Low Low Low Some concerns Some concerns
van Adrichem et a旭s, ゴグゲゼ ザ葦 Low Some concerns Low Low Low Some concerns
Zheng et a旭s, ゴグゲゼ 葦 Some concerns Low Some concerns Low Some concerns Some concerns
Geh旭ing et a旭s, 1998 ゴゼ Some concerns Some concerns Some concerns High Some concerns High
Bruntink et a旭s, ゴグゲゼ 9 Low Some concerns Low Low Some concerns Some concerns
Samama et a旭s, 2013 ザズ Low Some concerns Low Low Some concerns Some concerns
aOvera旭旭 risk of bias judgment ｪequa旭 to the most severe 旭eve旭 of bias found in any domainｫ was judged asr ゲｫ Low risk of biasr the study is judged to be at 旭ow risk of bias for a旭旭 domains for this resu旭tq ゴｫ 
Some concernsr the study is judged to have some concerns of bias in at 旭east one domain for this resu旭tq ザｫ High risk of biasr the study is judged to be at high risk of bias in at 旭east one domain for this resu旭t 
or have some concerns for mu旭tip旭e domains in a way that substantia旭旭y 旭owers confidence in the resu旭ts 
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TA B L E  ザ 科 Summary of outcomesr PE and major b旭eeding
Author, year Comparison
PE Major bleeding
LMWH Fondaparinux Control LMWH Fondaparinux Control
Events Total Events Total Events Total Events Total Events Total Events Total
Goe旭 et a旭s, 200928 LMWH vs p旭acebo 0 ゲゴゼ ｪグ鯵ｫ ､ ､ 0 ゲゲゲ ｪグ鯵ｫ 0 ゲゴゼ ｪグ鯵ｫ ､ ､ 0 ゲゲゲ ｪグ鯵ｫ
Jørgensen et a旭s, 200229 LMWH vs no 
treatment
0 ゾゾ ｪグ鯵ｫ ､ ､ 0 ゲグ葦 ｪグ鯵ｫ 0 ゾゾ ｪグ鯵ｫ ､ ､ 0 ゲグ葦 ｪグ鯵ｫ
Kock et a旭s, ゲゾゾズ30 LMWH vs no 
treatment
0 ゲゼ葦 ｪグ鯵ｫ ､ ､ 0 ゲ葦ザ ｪグ鯵ｫ 0 ゲゼ葦 ｪグ鯵ｫ ､ ､ 0 ゲ葦ザ ｪグ鯵ｫ
Kujath et a旭s, 199331 LMWH vs no 
treatment
0 ゲゴ葦 ｪグ鯵ｫ ､ ､ 0 ゲゴゼ ｪグ鯵ｫ 0 ゲゴ葦 ｪグ鯵ｫ ､ ､ 0 ゲゴゼ ｪグ鯵ｫ
Lapidus et a旭s, ゴググゼa32 LMWH vs p旭acebo 0 ジゾ ｪグ鯵ｫ ､ ､ 0 ジゼ ｪグ鯵ｫ 0 ジゾ ｪグ鯵ｫ ､ ､ 0 ジゼ ｪグ鯵ｫ
Lapidus et a旭s, ゴググゼb33 LMWH vs p旭acebo 0 ゲゲゼ ｪグ鯵ｫ ､ ､ 0 ゲグゾ ｪグ鯵ｫ 0 ゲゲゼ ｪグ鯵ｫ ､ ､ 0 ゲグゾ ｪグ鯵ｫ
Lassen et a旭s, 200234 LMWH vs p旭acebo 0 ゲ芦ザ ｪグ鯵ｫ ､ ､ 2 ゲ芦芦 ｪゲsゲ鯵ｫ 2 ゴゲゼ ｪグsゾ鯵ｫ ､ ､ 1 ゴゴゲ ｪグsズ鯵ｫ
Se旭by et a旭s, ゴグゲズ8 LMWH vs p旭acebo 0 ゲザグ ｪグ鯵ｫ ､ ､ 1 ゲゴ芦 ｪグs芦鯵ｫ 0 ゲザジ ｪグ鯵ｫ ､ ､ 0 ゲザゲ ｪグ鯵ｫ
van Adrichem et a旭s, ゴグゲゼ ザ葦 LMWH vs no 
treatment
4 ゼゲゾ ｪグs葦鯵ｫ ､ ､ ズ ゼゲ葦 ｪグsゼ鯵ｫ 0 ゼゲゾ ｪグ鯵ｫ ､ ､ 0 ゼゲ葦 ｪグ鯵ｫ
Zheng et a旭s, ゴグゲゼ葦 LMWH vs p旭acebo 0 ジゲゲ ｪグ鯵ｫ ､ ､ 0 ジグザ ｪグ鯵ｫ 0 ジゲゲ ｪグ鯵ｫ ､ ､ 0 ジグザ ｪグ鯵ｫ
Geh旭ing et a旭s, 1998ゴゼ LMWH vs aspirin 0 ゲジザ ｪグ鯵ｫ ､ ､ 0 ゲジジ ｪグ鯵ｫ 0 ゲジザ ｪグ鯵ｫ ､ ､ 0 ゲジジ ｪグ鯵ｫ
Bruntink et a旭s, ゴグゲゼ9 LMWH vs fon､
daparinux vs no 
treatment
0 ゾゴ ｪグ鯵ｫ 0 ゾゴ ｪグ鯵ｫ 2 ゾジ ｪゴsゲ鯵ｫ 0 ゾゴ ｪグ鯵ｫ 0 ゾゴ ｪグ鯵ｫ 0 ゾジ ｪグ鯵ｫ
Samama et a旭s, 2013ザズ LMWH vs 
fondaparinux
0 葦ゴゴ ｪグ鯵ｫ 2 葦ゴゲ ｪグsザ鯵ｫ ､ ､ 0 葦ゼグ ｪグ鯵ｫ 1 葦ゼジ ｪグsゲ鯵ｫ ､ ､
Abbreviationsr DVTp deep vein thrombosisq LMWHp 旭ow mo旭ecu旭ar weight heparinq PEp pu旭monary embo旭isms
ジザゴ科 |科 科架 HORNER ET AL.
effect of LMWH ｪORp グs葦ゾq ゾズ鯵 CrIr グsジザ､ゲsゲゴｫ compared with 
contro旭p a旭though the effect favored treatment with LMWHs
ザsジsジ科|科Asymptomatic DVTr a旭旭
Data were avai旭ab旭e from ゲグ studiess葦p芦pゾpゴゼ､ザグpザゴpザジpザズ The risk 
of asymptomatic DVT ｪa旭旭ｫ was 旭ower in adu旭t outpatients with 
旭ower 旭imb immobi旭ization who received LMWH ｪORp グsズゼq ゾズ鯵 
CrIr グsザゾ､グs芦ゴｫ and fondaparinux ｪORp グsゲジq ゾズ鯵 CrIr グsグズ､グsザゲｫ 
compared with contro旭s Fondaparinux is 旭ike旭y to be the most 
effective ｪprobabi旭ity of being the most effective ┎ ゲsググｫs
ザsジsズ科|科Pu旭monary embo旭ism
Data were avai旭ab旭e from a旭旭 ゲザ studiess葦p芦pゾpゴゼ､ザ葦 The risk of PE was 
旭ower in adu旭t outpatients with 旭ower 旭imb immobi旭ization who re､
ceived LMWH ｪORp グsゲゼq ゾズ鯵 CrIr グsグゲ､グs芦芦ｫ compared with con､
tro旭s A reduction in risk was a旭so found for fondaparinuxp a旭though 
the resu旭ts were inconc旭usive ｪORp グsジゼq ゾズ鯵 CrIr グsグゲ､ゾsズジｫs
ザsジs葦科|科Any VTE
Data were avai旭ab旭e from a旭旭 ゲザ studiess葦p芦pゾpゴゼ､ザ葦 The risk of any VTE was 
旭ower in adu旭t outpatients with 旭ower 旭imb immobi旭ization who received 
LMWH ｪORp グsズゴq ゾズ鯵 CrIr グsザゼ､グsゼゲｫ and fondaparinux ｪORp グsゲザq ゾズ鯵 
CrIr グsグズ､グsザグｫ compared with no thromboprophy旭axiss Fondaparinux 
is 旭ike旭y to be the most effective treatment ｪprobabi旭ity of being the 
most effective ┎ ゲsググｫs A旭though the resu旭ts suggest that the true ef､
fects may vary according to study characteristicsp the predictive distri､
bution sti旭旭 favored fondaparinux re旭ative to no prevention or p旭acebos
ザsジsゼ科|科Major b旭eeding
Data were avai旭ab旭e from a旭旭 ゲザ studiesp reporting major b旭eeding 
rates up to グsゾ鯵 with LMWHp グsゲ鯵 with fondaparinuxp and グsズ鯵 
with control. 葦p芦pゾpゴゼ､ザ葦 Major b旭eeding event rates across a旭旭 inc旭uded 
studies are high旭ighted in Tab旭e ザs With on旭y four events across a旭旭 
studiesp the effects of LMWH ｪORp ゲsジズq ゾズ鯵 CrIr グsグ芦､ザゴsゲゼｫ and 
fondaparinux on the risk of major b旭eeding were inconc旭usives
ザsジs芦科|科Comp旭iance and adverse events
Comp旭iance with study medication appeared genera旭旭y good within 
tria旭 participantsq eight studies reported ┒ゾグ鯵 comp旭iancep two 
studies between 芦グ鯵 and ゾグ鯵p and was unc旭ear in three studiess 
A sing旭e open､旭abe旭 study9 recorded reports of pain on injection in 
ゲsジ鯵 of participants within the intervention groups
There were few reported adverse events in the treated patientss 
Subjective and composite overa旭旭 adverse event rates ranged from 
グ鯵 to ジsグ鯵 across individua旭 studies with interventionp and グ鯵 to 
ゴsグ鯵 in contro旭 patientss Minor b旭eeding event rates varied from 
グ鯵 to ゲグsズ鯵 in the LMWH intervention groupsp グ鯵 to ゲsズ鯵 in the 
fondaparinux intervention groupsp and グ鯵 to 葦s芦鯵 in the contro旭 
groupss In the 旭argest RCT to datepザ葦 the most common adverse 
event ｪof infectionｫ occurred at a simi旭ar rate between intervention 
F I G U R E  ザ 科 Network diagram of different pharmaco旭ogica旭 thromboprophy旭axis interventions versus no thromboprophy旭axis for 
preventing VTEapbs DVTp deep vein thrombosisq LMWHp 旭ow mo旭ecu旭ar weight heparinq VTEp venous thromboembo旭isms aThe nodes are the 
interventionss The numbers against each outcome represent the number of times that each pair of interventions has been compareds There 
was one mu旭ti､arm study comparing LMWH versus fondaparinux versus contro旭s bDiagrams for specific outcomes depends on the number of 
studies that provide data and the number of non､zero event studiesq not a旭旭 outcomes invo旭ve feedback 旭oops
Control
(e.g. placebo, no 
treatment or aspirin)
Any VTE: 12 studies
Clinically relevant DVT: 9 studies
Clinically detected DVT (symptomatic): 10 studies
Asymptomatic DVT - all: 9 studies
Asymptomatic proximal DVT: 7 studies
Asymptomatic distal DVT: 7studies
Pulmonary embolism: 12 studies
Major bleeding: 12 studies
LMWH
(e.g. dalteparin, 
enoxaparin, tinzaparin)
Fondaparinux
Any VTE: 1 study
Clinically relevant DVT: 0 studies
Clinically detected DVT (symptomatic): 1 study
Asymptomatic DVT - all:1 study
Asymptomatic proximal DVT: 0 studies
Asymptomatic distal DVT: 0 studies
Pulmonary embolism: 1 study
Major bleeding: 1 study
Any VTE: 2 studies
Clinically relevant DVT: 1 study
Clinically detected DVT (symptomatic): 2 studies
Asymptomatic DVT - all: 2 studies
Asymptomatic proximal DVT: 1 study
Asymptomatic distal DVT: 1 study
Pulmonary embolism: 2 studies
Major bleeding: 2 studies
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and contro旭 groups ｪゲs葦鯵 vs ゴsグ鯵p respective旭yｫs In four studies 
active旭y reporting the incidence of heparin､induced thrombocyto､
peniap no cases were founds芦pゴゾpザゼpザ芦 No deaths in any study were 
deemed attributab旭e to either VTE or the use of interventions
ザsズ科|科Additiona旭 ana旭yses
The resu旭ts of the network meta､regressions are detai旭ed in 
Tab旭e Sザs The ana旭ysis showed that no covariate improved mode旭 
fits and therefore exp旭ained variation in treatment effectss
A sensitivity ana旭ysis exc旭uding the three studies at high risk of 
bias is detai旭ed in Tab旭e Sジs This ana旭ysis genera旭旭y had neg旭igib旭e im､
pact on the estimates of treatment effectp but as expectedp tended 
to increase uncertainty.
The effect of the type of thromboprophy旭actic agent used 
ｪcertoparinp da旭teparinp nadroparinp reviparinp and tinzaparinｫ was 
assessed using a separate NMAs This showed evidence to suggest 
that there were differences in the effects of the type of throm､
boprophy旭actic agent usedp inc旭uding between the different types 
of LMWHp with certoparin having the highest probabi旭ity of the 
greatest effect on any VTEs These findings shou旭d be treated with 
TA B L E  ジ 科 Resu旭ts of fixed effect and random effects NMA of different pharmaco旭ogica旭 thromboprophy旭axis interventions versus no 
thromboprophy旭axis
 
Fixed effect odds ratio ｪゾズ鯵 
CrI)
Random effects odds ratio ｪゾズ鯵 
CrI) Odds ratio ｪゾズ鯵 PrIｫ Prob. Best
C旭inica旭旭y detected DVT ｪsymptomaticｫr
LMWH グsジズ ｪグsゴゴ､グs芦ゾｫ グsジグ ｪグsゲゴ､グsゾゾｫ グsジゲ ｪグsグズ､ゴsザゲｫ 0.09
Fondaparinux グsゲゲ ｪグsグゲ､グs葦グｫ グsゲグ ｪグsグゲ､グsゾジｫ グsゲグ ｪグsググ､ゲsジ葦ｫ 0.91
None ､ ､ ､ 0.00
Asymptomatic DVT ｪproxima旭 segmentｫr
LMWH グsゴゴ ｪグsグズ､グsゼゲｫ グsゴゲ ｪグsグジ､グs芦ゴｫ グsゴゲ ｪグsグゴ､ゲsザジｫ グs葦ザ
Fondaparinux グsゴゾ ｪグsグザ､ゴsザズｫ グsゴ芦 ｪグsグゴ､ザsジゴｫ グsゴ芦 ｪグsグゲ､ジsジゾｫ グsザ葦
None ､ ､ ､ 0.01
Asymptomatic DVT ｪdista旭ｫr
LMWH グs葦ゾ ｪグsジゼ､ゲsグゲｫ グs葦ゾ ｪグsジザ､ゲsゲゴｫ グs葦ゾ ｪグsゴゾ､ゲs葦ゴｫ 0.00
Fondaparinux グsゲゲ ｪグsグジ､グsゴゼｫ グsゲゲ ｪグsグザ､グsザズｫ グsゲゲ ｪグsグザ､グsジゴｫ 1.00
None ､ ､ ､ 0.00
Asymptomatic DVT ｪa旭旭ｫr
LMWH グsズゼ ｪグsジゴ､グsゼゼｫ グsズゼ ｪグsザゾ､グs芦ゴｫ グsズゼ ｪグsゴ芦､ゲsゲゴｫ 0.00
Fondaparinux グsゲジ ｪグsグゼ､グsゴゼｫ グsゲジ ｪグsグズ､グsザゲｫ グsゲジ ｪグsグズ､グsザ芦ｫ 1.00
None ､ ､ ､ 0.00
Pu旭monary embo旭ismr
LMWH グsザグ ｪグsグゼ､グsゾ葦ｫ グsゲゼ ｪグsグゲ､グs芦芦ｫ グsゲ芦 ｪグsググ､ゲsゼゾｫ グsゼジ
Fondaparinux グs葦ジ ｪグsグズ､ゼsゴ葦ｫ グsジゼ ｪグsグゲ､ゾsズジｫ グsジ芦 ｪグsグゲ､ゲゼsズザｫ グsゴズ
None ､ ､ ､ 0.01
Major b旭eedingr
LMWH ゲs葦グ ｪグsゲジ､ゴズs葦ゼｫ ゲsジズ ｪグsグ芦､ザゴsゲゼｫ ゲsジ葦 ｪグsグ葦､ジゴs芦ゼｫ グsザゼ
Fondaparinux ゲジザ芦グ ｪグsジ芦､ゾsゾEゲジｫ 芦ジゴゴ ｪグsザゴ､ゲsザEゲジｫ 芦ジゴゲ ｪグsゴゾ､ゲsザEゲジｫ 0.03
None ､ ､ ､ グsズゾ
C旭inica旭旭y re旭evant DVTa
LMWH グsジザ ｪグsゴゴ､グsゼゾｫ グsジグ ｪグsゲ葦､グs芦ズｫ グsジグ ｪグsグゼ､ゲsゼ葦ｫ 0.22
Fondaparinux グsゴズ ｪグsグゼ､グs芦ゴｫ グsゴザ ｪグsグザ､ゲsザ葦ｫ グsゴザ ｪグsグゴ､ ゴsゲゲｫ グsゼゼ
None ､ ､ ､ 0.01
Any VTEr
LMWH グsズザ ｪグsジゲ､グs葦ゼｫ グsズゴ ｪグsザゼ､グsゼゲｫ グsズゴ ｪグsゴザ､ゲsゲゴｫ 0.00
Fondaparinux グsゲジ ｪグsグゼ､グsゴズｫ グsゲザ ｪグsグズ､グsザグｫ グsゲザ ｪグsグジ､グsザゾｫ 1.00
None ､ ､ ､ 0.00
Abbreviationsr CrIp credib旭e interva旭q PrIp predictive interva旭s
aC旭inica旭旭y re旭evant DVT was defined as the cumu旭ative figure of any symptomatic OR asymptomatic proxima旭 DVTs 
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cautionp based on the heterogeneity between studies and the 旭ow 
event rates.
ジ科 |科DISCUSSION
ジsゲ科|科Summary of evidence
Our NMA shows that thromboprophy旭axis with LMWH for patients 
with 旭ower 旭imb immobi旭ization after injury approximate旭y ha旭ves the 
odds of any VTE in these studiess Thromboprophy旭axis with fonda､
parinux appears to have a greater effect on reducing the risk of DVT 
and is 旭ike旭y to be more effective than LMWHs Event rates for symp､
tomatic DVT and PE in untreated patients were genera旭旭y 旭ow across 
the studiesp so an approximate ha旭ving of odds may resu旭t in a sma旭旭 
abso旭ute risk reductions
Major b旭eeding is very uncommonp so the effect of thrombopro､
phy旭axis on major b旭eeding in this group is uncertains Meta､regression 
did not identify any re旭iab旭e evidence of effect modification by key 
covariates.
ジsゴ科|科Strengths and 旭imitations
Our NMA synthesized data from 葦芦ズゼ participants in ゲザ randomized 
tria旭ss This represents a 旭argep methodo旭ogica旭旭y robust data set 
across mu旭tip旭e settings used to simu旭taneous旭y estimate of re旭ative 
treatment effectss
Our ana旭ysis was inevitab旭y 旭imited by the primary datas The va､
riety of settings and patient groups may be a strengthp but gener､
ated evidence of heterogeneity of treatment effect across studies 
for many of the outcomess Previous work has shown evidence of 
pub旭ication bias such that studies with nonsignificant or unfavorab旭e 
resu旭ts on this topic are perhaps 旭ess 旭ike旭y to be pub旭ishedp have a 
de旭ay to pub旭icationp or invo旭ve se旭ective旭y reporting outcomess39 
These issues have the potentia旭 to exaggerate any benefit to the in､
tervention seen at NMAs
The studies were judged main旭y to have 旭ow risk of bias or some 
concerns on旭y for most qua旭ity criterias Howeverp three tria旭s were 
judged as having a high risk of bias on the basis of outcome ascertain､
ment being potentia旭旭y subject to bias in an open､旭abe旭 tria旭sゴゼpザグpザゲ 
This is particu旭ar旭y re旭evant to the issue of symptomatic VTE as an 
outcomes Severa旭 of these open､旭abe旭 tria旭s performed routine so､
nographic screening on remova旭 of p旭aster castp fo旭旭owed by c旭inica旭 
assessments This methodo旭ogy introduces a high risk of bias with 
symptomatic VTE outcomesq patients may have been inf旭uenced by 
the sonographerp or party to the u旭trasound resu旭ts before disc旭os､
ing information on symptomato旭ogys A sensitivity ana旭ysis exc旭uding 
these studies genera旭旭y had neg旭igib旭e impact on the estimates of 
treatment effect butp as expectedp tended to increase uncertaintys 
This ana旭ysis does not take into account that severa旭 of the c旭inica旭 
events were 旭ike旭y not representative for events that wou旭d 旭ead a 
patient to active旭y seek medica旭 assistance ｪisesp tru旭y symptomatic 
eventsｫs This is ref旭ected in the high旭y varying risks between stud､
ies found in Tab旭e ザs A further breakdown of symptomatic VTE out､
comes is provided in Tab旭e Sズ for transparencys
We inc旭uded one tria旭ゴゼ that administered high､dose aspirin to 
the contro旭 groupp on the basis that at the time of review nationa旭 UK 
guide旭ines on venous thromboembo旭ism CGゾゴ40 and NG芦ゾ41 did not 
consider aspirin or other antip旭ate旭et agents to be appropriate for 
VTE prophy旭axis in iso旭ationsジゴpジザ If aspirin has a significant prophy､
旭actic effectp then this tria旭 may underestimate the beneficia旭 effect 
of additiona旭 thromboprophy旭axiss As suchp inc旭usion of this tria旭 in 
the meta､ana旭ysis wou旭d on旭y confer bias toward a negative resu旭ts
The primary studies had a number of se旭ection criteria that 旭imit 
our abi旭ity to app旭y the findings to certain popu旭ationss Patients with 
a high risk of VTE ｪsuch as those with active cancerp thrombophi旭iap 
previous VTEp or pregnancy｠puerperiumｫ and those with an in､
creased risk of b旭eeding were often exc旭udeds The studies genera旭旭y 
inc旭uded patients with rigid immobi旭ization rather than those with a 
degree of movement or a removab旭e cast or sp旭intp so the findings 
may on旭y be app旭icab旭e to those with fu旭旭 immobi旭izations
In additionp inc旭uded studies range across a ゴズ､year period of 
pub旭icationp during which it is 旭ike旭y that management strategies have 
significant旭y evo旭veds Both immobi旭ization and acute surgica旭 inter､
vention techniques have become 旭ess invasive over timep with ear旭y 
mobi旭ization and enhanced recovery routine旭y promoteds There is 
a旭so ongoing debate about the merits of thrombosis research using 
asymptomatic VTE as any form of outcomes Concerns inc旭ude the 
use of variab旭e criteria and assessment strategies to confirm disease 
and the impact of observer bias in unb旭inded studies using these 
outcomes.ジジpジズ Converse旭yp some authors high旭ight the evidence sug､
gesting asymptomatic VTE to be a potentia旭 indicator of the re旭ative 
risk of symptomatic VTE and even fata旭 PEsジ葦 Thromboprophy旭axis 
after 旭ower 旭imb injury has specific cha旭旭enges in these areasp given 
the variation in management and the inevitab旭e presence of 旭eg 
symptoms at base旭ine injury ｪswe旭旭ing and painｫs To what degree do 
symptoms need to change to suggest a risk of symptomatic VTE to 
both the patient and c旭iniciann Both these issues are perhaps re､
f旭ected in the high旭y variab旭e incidence of VTE across the inc旭uded 
studiesp ranging from ゲs芦鯵 to ジグsジ鯵sジゼ We present our outcomes in 
this study stratified by symptomatic disease and anatomica旭 旭ocation 
of VTE to address these issuess
The ana旭ysis inc旭uded a substantia旭 number of participants but 
the number of events for some outcomes were very 旭owp or zerop 
inc旭uding zero events in two arms of a studys As a consequencep not 
a旭旭 studies provide estimates of re旭ative treatment effect for a旭旭 out､
comess We were unab旭e to produce precise estimates of the effect 
of thromboprophy旭axis upon major b旭eeding or estimate the effect 
of treatment on deaths The 旭ow rate of b旭eeding provides some reas､
surance that thromboprophy旭axis is not causing a c旭inica旭旭y import､
ant rate of serious adverse outcome in this popu旭ation but this may 
not be app旭icab旭e to patients with a higher risk of b旭eedings Other 
surrogate datasetsp such as patients receiving thromboprophy旭axis 
for knee arthroscopy can provide further re旭evant information on 
b旭eeding risks48 This information cou旭d be used to support shared 
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decision､makings Howeverp the popu旭ation undergoing e旭ective ar､
throscopy has key differences to our popu旭ation of interestp inc旭ud､
ing acute exposure to surgica旭 b旭eeding riskp hospita旭izationp and the 
absence of b旭unt forced injurys As suchp extrapo旭ation of b旭eeding 
risk to conservative旭y managed ambu旭atory patients has significant 
caveats.
ジsザ科|科Comparison to previous research
Two systematic reviews have been recent旭y pub旭ished on the use of 
pharmaco旭ogica旭 thromboprophy旭axis for patients with temporary 
immobi旭ization resu旭ting from acute injurys Hickey et a旭s inc旭uded 
seven studiesp focussing on旭y on LMWH as an intervention and re､
porting an OR of グsゴゾ for the deve旭opment of symptomatic DVTp 
with 旭imited precision ｪゾズ鯵 CI グsグゾ､グsゾズｫs49 In additionp they note 
a 旭ow major b旭eeding rate ｪグsゲ鯵ｫ with LMWHs These findings are in 
keeping with the resu旭ts of this studys
An updated Cochrane meta､ana旭ysis by Zee et a旭sズグ reported data 
from eight tria旭spゾpゴゾ､ザジpザ葦 inc旭uding ザ葦芦グ participants that compared 
thromboprophy旭axis with no treatment or p旭acebos They found that 
LMWH was associated with a significant旭y reduced risk of any DVT 
ｪORp グsジズq ゾズ鯵 CIr グsザザ､グs葦ゲｫ and symptomatic VTE ｪORp グsジグq ゾズ鯵 
CIr グsゴゲ､グsゼ葦ｫs Zee et a旭sズグ exc旭uded four tria旭s that were inc旭uded in 
our ana旭ysis ｪGoe旭 et a旭s28p Se旭by et a旭s8p Geh旭ing et a旭spゴゼ and Samama 
et al.ザズｫp whereas one additiona旭 tria旭 was pub旭ished after their up､
dated meta､ana旭ysis ｪZheng et a旭s葦ｫs Two of the tria旭s were exc旭uded 
because they focused on operative旭y treated fractures rather than 
immobi旭ization ｪGoe旭 et a旭s28p Se旭by et a旭s8ｫp one because the compar､
ator was aspirin ｪGeh旭ing et a旭sゴゼｫ and one because the intervention 
was fondaparinux rather than LMWH ｪSamama et a旭sｫ.ザズ The inclu､
sion of these tria旭s has ensured that our ana旭ysis is more comprehen､
sivep but possib旭y at the expense of greater heterogeneitys
In additionp our study is a旭so the first to perform network me､
ta､ana旭ysis ｪNMAｫ of different treatment optionss NMA a旭旭ows indirect 
comparison of interventions and faci旭itates assessment of benefits 
and harms for variab旭e treatment options for a given c旭inica旭 sce､
narios This methodo旭ogy has recent旭y been used by the Wor旭d Hea旭th 
Organization to inform c旭inica旭 guide旭ine deve旭opmentp is consid､
ered to be a high 旭eve旭 of evidencep and has specific advantages for 
VTE research in which mu旭tip旭e treatment options exist for a sing旭e 
patho旭ogysズゲ
ジsジ科|科Meaning of the study
Thromboprophy旭axis in 旭ower 旭imb immobi旭ization resu旭ting from in､
jury approximate旭y ha旭ves the odds of any VTE and is associated with 
reductions in the risks of symptomatic DVT and PEs
The impact of this reduction in odds is 旭ike旭y to have variab旭e c旭in､
ica旭 impact dependent on base旭ine risks If base旭ine risk for symptom､
atic disease is consistent旭y 旭ow across a popu旭ationp then ha旭ving the 
odds may resu旭t in a 旭ow abso旭ute risk reduction ｪARRｫ and a high 
number needed to treat ｪNNTｫs This issue is demonstrated in Tab旭e ザp 
in which the summation of events for c旭inica旭旭y re旭evant DVT resu旭ts 
in a reduction from a ゲsゼ鯵 event rate ｪcontro旭ｫ to a ゲsグ鯵 event rate 
ｪLMWHｫs Many c旭inicians may consider this benefit too 旭imited to jus､
tify the cost and potentia旭 adverse event profi旭e of LMWHs Howeverp 
assuming the re旭ative treatment effect is consistentp a se旭ected popu､
旭ation with a higher base旭ine risk ｪidentified through risk scoring or a旭､
ternative methodｫ wou旭d be expected to receive a 旭arger proportiona旭 
ARR and a resu旭ting 旭ower NNTp which may produce a different c旭in､
ica旭 decisions For this reasonp sing旭e reported ARR and NNT derived 
from meta､ana旭ysis have been reported as potentia旭旭y mis旭eadings
The evidence found was 旭imited to LMWH and fondaparinuxq 
it remains unc旭ear whether these findings can be extrapo旭ated to 
DOAC agents or other moda旭itiess This is an important consideration 
because the abso旭ute risks of c旭inica旭旭y re旭evant VTE may vary across 
popu旭ationsq patients who may not be wi旭旭ing to submit to the in､
convenience of parentera旭 treatment to reduce a re旭ative旭y sma旭旭 risk 
may be prepared to use ora旭 therapys
Within the meta､regression ana旭ysesp we were unab旭e to identify 
any evidence to direct旭y support stratified thromboprophy旭axiss We 
found no association between treatment effect and patient charac､
teristicsp type of injuryp treatment methodp or duration of prophy旭axiss 
Severa旭 authors have recent旭y suggested that se旭ection of patients for 
thromboprophy旭axis may be appropriate on the basis of an increased 
base旭ine risk39q it does not appear from our ana旭ysis adjusting for base､
旭ine risk that prophy旭axis shou旭d be offered based on an expectation 
of greater effectiveness in any specific groups We did not assess risk 
factors at a patient 旭eve旭 within this work and so cannot draw any con､
c旭usions on the merits of risk adjusted thromboprophy旭axiss
ジsズ科|科The direction of future research
A旭though our findings suggest that thromboprophy旭axis cou旭d reduce 
the rate of symptomatic eventsp further study of cost effectiveness 
is needed given the 旭ow abso旭ute risks In additionp stratified throm､
boprophy旭axis may be ab旭e to se旭ect out patients at highest risk and 
maximize potentia旭 c旭inica旭 and cost effectivenesss Severa旭 risk as､
sessment mode旭s ｪRAMｫ have a旭ready been derived for use in this 
patient popu旭ationp aiming to tai旭or thromboprophy旭axis strategies at 
presumed high risk and 旭imit financia旭 costsp opportunity costsp and 
side effectssゲゴpズゴpズザ The current evidence base for RAMs is very 旭im､
itedp and estimates of sensitivity and specificity are subject to sub､
stantial uncertainty.ゲゼ Improving the evidence base for RAMs is a key 
research priority and externa旭 va旭idation studies are urgent旭y neededs 
In addition to dichotomous RAMsp individua旭ized treatment cou旭d po､
tentia旭旭y be optimized by further adaptation in very high､risk groups 
deemed to warrant thromboprophy旭axis ｪesgsp higher dosingp 旭onger 
durationｫs This 旭atter question is yet to be addressed in the 旭iteratures
Ora旭 medications cou旭d provide the benefits of thromboprophy､
旭axis without the costsp inconveniencep and discomfort of injectionss 
Howeverp evidence of effectiveness in our review was re旭ated on旭y 
to LMWH or fondaparinuxs If further research identifies a high､risk 
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popu旭ation that unequivoca旭旭y benefit from thromboprophy旭axisp the 
use of direct ora旭 anticoagu旭ants cou旭d potentia旭旭y be compared with 
LMWH to assess differences in costp c旭inica旭 outcomep and patient 
satisfactions
It is current旭y unc旭ear whether peop旭e with 旭imited 旭ower 旭imb 
immobi旭ization ｪsuch as sp旭ints that a旭旭ow some movement or 
removab旭e sp旭ints or castsｫ carry simi旭ar risks of VTE to those 
with fu旭旭 immobi旭izations A study of this popu旭ation cou旭d deter､
mine the risk of VTE and potentia旭旭y identify patient､旭eve旭 risk 
predictorss
ズ科 |科CONCLUSIONS
Thromboprophy旭axis for patients with 旭ower 旭imb immobi旭ization 
after injury appears to be c旭inica旭旭y effectivep reducing the odds of 
symptomatic VTEs Given the 旭ow abso旭ute risk of VTE in a broad pop､
u旭ationp individua旭ized risk assessment and shared decision making 
may be optima旭s This strategy requires further supporting researchs
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